Reprocessing efficacy, functional integrity and biological safety are connected—but they are not the same conclusion.
For a manufacturer-labelled reusable instrument, evaluate whether cleaning, disinfection, sterilization, drying, transport and repeated cycles can change patient-contacting residues, surfaces, coatings, corrosion, wear, particles or degradation. Select new, processed or end-of-life states according to the question and justify the cycle count.
A reusable instrument is placed on the patient repeatedly after a labelled sequence of handling and reprocessing. The biological evaluation must therefore remain connected to the condition that sequence creates—not only to the unused production device.
Scope: manufacturer-labelled reusable surgical instruments
This guide addresses devices the manufacturer intends and labels for reuse. It does not address third-party reprocessing of devices labelled for single use, which can raise a different regulatory framework. Begin with the intended patient contact, procedure, user, maximum useful life and complete validated reprocessing instructions.
Keep three questions visible: can the process reliably clean and prepare the device for reuse; does the device continue to function safely; and does the post-process device remain biologically acceptable? Evidence for one does not automatically answer the others.
Map the complete labelled reprocessing cycle
Follow the device from point-of-use handling through containment, transport, disassembly, pre-cleaning, manual or automated cleaning, rinsing, disinfection, drying, inspection, lubrication, reassembly, packaging, sterilization and storage as applicable. Record chemicals, water quality, temperatures, contact times, equipment, reusable accessories and maximum delays permitted by the instructions.
ISO 17664-1 addresses information the manufacturer provides for processing critical and semi-critical devices. FDA's reprocessing guidance focuses on validated methods and labelling. These controls support the biological evaluation but do not replace it.
How reprocessing can affect biological evidence
| Source | Possible change | Evidence question |
|---|---|---|
| Cleaning chemistry | Detergent, disinfectant or rinse residues. | Are residues controlled under labelled use and realistic rinsing? |
| Repeated cycles | Corrosion, oxidation, coating wear, crazing or surface roughness. | Does useful-life simulation create a different patient-contacting state? |
| Lubrication and maintenance | Added substances or migration onto contact surfaces. | Are labelled maintenance materials represented and controlled? |
| Mechanical use | Wear debris, particles, damaged joints or retained soil. | Is simulated use needed alongside reprocessing to represent end of life? |
| Sterilization | Material, coating, residue or packaging interaction changes. | Which cycle and cumulative condition answer the biological question? |
These are hypotheses to evaluate. Do not state that reprocessing necessarily produces harmful residues or degradation; use material knowledge, validation data, surface inspection, chemistry, complaints and other evidence to determine relevance.
New, processed and end-of-life representative states
The correct article depends on the question. An unused device may represent the initial marketed state. A device after one labelled cycle may address an early processing residue. A justified maximum-cycle or end-of-life condition may challenge cumulative surface change. Sometimes simulated clinical use must accompany reprocessing; in other cases it would introduce an unrelated variable.
There is no universal requirement to test every state or a fixed number of cycles. Justify cycle count from labelled life, material vulnerability, validation design, inspection findings and the biological mechanism under review. If a family is represented by one instrument, compare geometry, hinges, lumens, coatings, materials and cleaning difficulty rather than choosing only the largest device.
Join reprocessing, functional and biological evidence without merging conclusions
- Reprocessing validation shows that the labelled process performs as intended under specified conditions.
- Functional and integrity testing addresses continued mechanical or performance safety.
- Material and surface characterization can identify post-cycle changes relevant to exposure.
- Chemical characterization and toxicological assessment can evaluate detected constituents where appropriate.
- Biological evidence addresses applicable biological effects within the complete risk-based evaluation.
Build a traceability map that shows which configuration, cycle state and question each report covers. A passing cleaning validation does not establish biological safety, and a biological test does not validate cleaning instructions.
When to reopen the assessment
Reassess after changes to material, coating, passivation, supplier, manufacturing, cleaning agent, water specification, equipment, sterilization method or site, reprocessing instructions, claimed useful life, geometry or intended use. Also consider complaints, residue trends, corrosion, staining, coating loss, particles, functional failures or new clinical-use information.
The update should identify the authorised baseline, describe the change, determine which evidence remains applicable, and hold implementation until applicable quality and regulatory decisions are complete.
Reusable-instrument biological-evidence review checklist
- Define contact site, duration, frequency and labelled useful life.
- Map every step and material in the labelled reprocessing cycle.
- Identify residues, surface changes, corrosion, wear and particles that are plausible for this design.
- Choose and justify the unused, processed or end-of-life representative state.
- Link cleaning validation, integrity, chemistry, toxicology and biological evidence without merging conclusions.
- Document device-family coverage and hard-to-clean features.
- Define inspection limits, change triggers and post-market signals.
- Obtain qualified reprocessing, biological-safety and regulatory review.
This article does not validate a reprocessing method, set an acceptable cycle count, approve an end-of-life article or determine biological safety.
Primary sources and standards records
- FDA: Reprocessing Medical Devices in Health Care Settings — validation methods and labelling guidance
- FDA information for reusable-device manufacturers
- ISO 17664-1:2021 public record — manufacturer processing information
- ISO 10993-1:2025 public record
- FDA guidance on use of ISO 10993-1
- ISO 14971:2019 public record
- Consolidated Regulation (EU) 2017/745
Source status: checked August 22, 2026. Standards records describe scope; consult controlled standards and current jurisdiction-specific requirements for device decisions.
Why this perspective is practical
Arvind Rathore is the founder of MedDev Advisory, where his work focuses on ISO 10993 biological-evaluation strategy and documentation. Before establishing the practice, he was a Marie Skłodowska-Curie Early Stage Researcher at INSERM U1026 Biotis within the ImplantSens network. His research covered implantable electrochemical biosensors, cytotoxicity, oxidative stress, sterilization effects and biomaterial–cell interactions, with research placements in France, Germany and Sweden. Peer-reviewed work in Bioelectrochemistry and Advanced Sensor Research also informs his evidence-led approach. Read more about Arvind Rathore.
Need a reusable-instrument reprocessing and biological-evidence record?
The companion pack connects labelled cycles, device states and evidence domains. It does not validate processing, set cycle counts or replace qualified review.